A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
With the increase in commercial alligator farming in countries including Thailand, the United States, Australia, South Africa, and South East Asia, crocodile fat and oil became a commercial product that can be used in a number of ways such as medicine, skin care products, and as a feedstock for biodiesel. Natural oils are extensively used in cosmetics and as treatment for a growing number of conditions. According to Vermaak, the natural products industry is a multibillion-dollar industry and has grew enormously in the years up to 2011. Crocodile oil as an oil mainly containing fatty acids contribute to beneficial properties in cosmetics and personal care products. More specifically, crocodile oil is also used in the tanning industry. The oil can range from about $US4 for a tube of crocodile lip balm to about $US104 for a large jar of pure crocodile oil balm. Businesses consider the capability to convert crocodile fat to a marketable oil. They can capitalise on "first-mover advantage" due to crocodile oil benefits. Golden 8 Skincare is an Australian company, using crocodile oil as the main ingredient of its product. The company's description of the product include "Packed full of Omegas 3,6 7 and 9 to help in the healing of skin conditions due to its Natural Moisturising Factor (NMF) Crocodile Oil helps prevents dermal irritation and regenerates the skin whilst providing the skin its daily dose of Omegas to produce clear, glowing, healthy skin." Crocodile oil lotions and other products derived from crocodile fat can be seen sold online for personal use.
=== NAADP activators === NAADP is charged and cannot cross cell membranes. Therefore, an inactive, lipophilic ester precursor (NAADP/AM) has been synthesised which crosses membranes and rapidly regenerates NAADP in the cytosol following the action of endogenous esterases. Caged NAADP is an inactive, membrane-impermeant analog of NAADP that can be introduced into cells by microinjection or a patch pipette. Flash photolysis with a UV light source rapidly converts this into NAADP, allowing the experimenter to precisely manipulate NAADP levels in time and space.
In Somaliland, the Isaaq Sultanate was established in 1750. The Isaaq Sultanate was a Somali kingdom that ruled parts of the Horn of Africa during the 18th and 19th centuries. It spanned the territories of the Isaaq clan, descendants of the Banu Hashim clan, in modern-day Somaliland and Ethiopia. The sultanate was governed by the Rer Guled branch established by the first sultan, Sultan Guled Abdi, of the Eidagale clan. According to oral tradition, prior to the Guled dynasty the Isaaq clan-family were ruled by a dynasty of the Tolje'lo branch starting from, descendants of Ahmed nicknamed Tol Je'lo, the eldest son of Sheikh Ishaaq's Harari wife. There were eight Tolje'lo rulers in total, starting with Boqor Harun (Somali: Boqor Haaruun) who ruled the Isaaq Sultanate for centuries starting from the 13th century. The last Tolje'lo ruler Garad Dhuh Barar (Somali: Dhuux Baraar) was overthrown by a coalition of Isaaq clans. The once strong Tolje'lo clan were scattered and took refuge amongst the Habr Awal with whom they still mostly live. In the late 19th century, after the Berlin Conference of 1884, European powers began the Scramble for Africa. In that year, a British protectorate was declared over part of Somalia, on the African coast opposite South Yemen. Initially, this region was under the control of the Indian Office, and so administered as part of the Indian Empire; in 1898 it was transferred to control by London.
Sources: en.wikipedia.org
== Deliberate targeting == A 2026 United Nations report found reasonable grounds to conclude that Palestinian children had been deliberately targeted by Israeli security forces during the conflict. The report documented cases of children being killed by single, precise gunshots by snipers and drones, frequently in the head or upper torso, suggesting a deliberate intention to target them rather than incidental harm. Doctors who had undertaken medical missions in Gaza told the Commission that it appeared Israeli Defense Force (IDF) were engaging in a "game of target practice", with different parts of children's bodies reportedly being targeted on different days. The report also documented systematic attacks on child-essential infrastructure that had contributed to preventable child deaths and long-term disabilities. The Commission further examined dehumanising rhetoric by political leaders, soldiers and public figures, which it said contributed to an environment in which violence against Palestinian children was more readily accepted.
== Treatment == The treatment of arthrogryposis includes occupational therapy, physical therapy, splinting and surgery. An approach that occupational therapists use is orthopedic management. Using casts in order to correct joint deformities can be very effective since the joints can be misaligned and present with deformities. Another vital intervention that occupational therapists use to treat arthrogryposis, is range of motion exercises. This is in order to increase joint mobility. The primary long-term goals of these treatments are increasing joint mobility and muscle strength and the development of adaptive use patterns that allow for walking and independence with activities of daily living. Since arthrogryposis has many different types, the treatment varies between patients depending on the symptoms.
==== United States market (brands, formats, and recent changes) ==== The leading seller in the e-cigarette market in the US is the Juul e-cigarette, which was introduced in June 2015. As of August 2018, Juul accounts for over 72% of the US e-cigarette market monitored by Nielsen, and its closest competitor—RJ Reynolds' Vuse—makes up less than 10% of the market. Juul rose to popularity quickly, growing by 700% in 2016 alone. On 17 July 2018 Reynolds announced it will debut in August 2018 a pod mod type device similar Juul. The popularity of the Juul pod system has led to a flood of other pod devices hitting the market. Since 2018 the US e-cigarette market has shifted. During January 2020-December 2022, disposable cigarette unit share increased from 24.7% to 51.8%, while prefilled cartridge share decreased from 75.2% to 48.0%. For the four-week period ending December 25, 2022, the top-selling brands were Vuse, JUUL, Elf Bar, NJOY, and Breeze Smoke. In the 52 weeks ended June 15, 2024, Vuse Alto products represented approximately 40% of U.S. e-cigarette sales in stores tracked by NielsenIQ, according to an analyst cited by The Wall Street Journal. In the US the Federal Trade Commission reported that e-cigarette product sales for major reporting manufacturers rose to $2.703 billion in 2019 and then declined to $2.224 billion in 2020, with the FTC noting this may reflect a shift to other market participants. In US retail scanner data, the number of e-cigarette brands increased from 184 in January 2020 to 269 in December 2022.
European lawmaker Hannah Neumann said that during the ceasefire, the repression within Iran is getting worse, and criticized that diplomatic efforts have not included the rights of Iranian people. US senator Bill Cassidy said that the ongoing talks with Iran were to make sure that they would not be able to develop a nuclear weapon. Ahead of the negotiation process, Trump told reporters that the outcome of the negotiations did not matter to him because his country supposedly defeated Iran militarily already. The same night that the negotiations were occurring, he was at an Ultimate Fighting Championship (UFC) fight event with Secretary of State Marco Rubio; it is unknown whether Trump knew of the negative outcome of the negotiation round at the time. In a later congressional hearing, senator Jacky Rosen told Rubio that she was shocked to see that Rubio, as secretary of state, chose to accompany Trump for a party at the UFC instead of taking part in talks with Iran during the Islamabad talks with Vance. The day after the Islamabad and UFC events ended, Trump announced that he would immediately enact a naval blockade against Iran. In late April, after the first round of talks had already concluded, Iranian representatives wouldn't arrive for the anticipated second round of talks expected later in the month.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.